This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
=== Measurements of elevated copper status === Although a number of indicators are useful in diagnosing copper deficiency, there are no reliable biomarkers of copper excess resulting from dietary intake. The most reliable indicator of excess copper status is liver copper concentration. However, measurement of this endpoint in humans is intrusive and not generally conducted except in cases of suspected copper poisoning. Increased serum copper or ceruolplasmin levels are not reliably associated with copper toxicity as elevations in concentrations can be induced by inflammation, infection, disease, malignancies, pregnancy, and other biological stressors. Levels of copper-containing enzymes, such as cytochrome c oxidase, superoxide dismutase, and diaminase oxidase, vary not only in response to copper state but also in response to a variety of other physiological and biochemical factors and therefore are inconsistent markers of excess copper status. A new candidate biomarker for copper excess as well as deficiency has emerged in recent years. This potential marker is a chaperone protein, which delivers copper to the antioxidant protein SOD1 (copper, zinc superoxide dismutase). It is called "copper chaperone for SOD1" (CCS), and excellent animal data supports its use as a marker in accessible cells (e.g., erythrocytes) for copper deficiency as well as excess. CCS is currently being tested as a biomarker in humans.
Total Logistic Control is a supply chain company started around 1902 by George K. Taylor. The company began as a regional distributor known as Taylor Cold Storage, which operated frozen warehouse operations for other regional food companies in Great Lakes region. Around 1930, they merged with Wisconsin Cold Storage. In 1958, Taylor became the first public refrigerated warehouse to offer consolidated LTL distribution to its customers. In the 1960s, their total freezer capacity hit 10,000,000 cu ft (280,000 m3). Taylor introduced TINMAN, the Total INformation MANagement system, in 1976, becoming the first firm in the industry to offer online inventory management. In 1982, a flood wiped out the company warehouses, creating the opportunity to refocus the company on third-party logistics as Total Logistic Control. They achieved Foreign Trade Zone status in 1990. Acquired by 'Christiana Companies, Inc' in 1994, the company went into a growth phase. Merging with Wiscold in 1996, starting a Logistics Management Services division in 1999, and then acquiring the ProSource Group in 2000 (offering turnkey facility design). In 2002, they purchased two over-the-road trucking companies of TSI and Birkmire Trucking; taking their fleet total to around 400 tractor-trailers. They were acquired by SuperValu in 2005 and moved their corporate offices to Holland, MI in 2008. Today, TLC is a Source-to-Shelf supply chain company targeting the consumer goods supply chain. 97% of the products they touch end up in retail. Last year that was over 2 billion cases (CEs).
===== Rpn1 ===== Ubiquitin binds Rpn1 via two sites, termed the T1 and T2 sites that were identified using NMR. Rpn1 also provides a docking site for Ubp6. The affinities for ubiquitin for these receptors in isolation has been measured through a variety of methods. They are all in the micromolar range, however a substrate that has both a ubiquitin signal and an unstructured region has a Michaelis menten constant in the hundreds of nanomolar range, suggesting that the unstructured region in key in engaging a substrate.
Sources: en.wikipedia.org
== Committees == CLSI documents are developed by committees consisting of experts in medical testing or related aspects. Each CLSI committee produces consensus documents related to a specific discipline.
== Adverse effects == Data from clinical trials submitted to regulatory authorities showed that rimonabant caused depressive disorders or mood alterations in up to 10% of subjects and suicidal ideation in around 1%, and in Europe it was contraindicated for people with any psychiatric disorder, including clinical depression. Data from a large, randomized, clinical trial (CRESCENDO) with > 9,000 patients receiving rimonabant treatment demonstrated a rate of psychiatric adverse events (anxiety, depression, depressed mood, or insomnia) of greater than 30%. Additionally, nausea and upper respiratory tract infections were very common adverse effects (occurring in more than 10% of people); common adverse effects (occurring in between 1% and 10% of people) included gastroenteritis, anxiety, irritability, insomnia and other sleep disorders, hot flushes, diarrhea, vomiting, dry or itchy skin, tendonitis, muscle cramps and spasms, fatigue, flu-like symptoms, and increased risk of falling. The FDA's advisory committee concurred with concerns raised by the review divisions. Based on human and on animal data, it appeared that the therapeutic window was narrow. EMA postmarketing surveillance data suggested that the risk of psychiatric disorders in people taking rimonabant was doubled.
== Known members == For a key to the single-letter sequences, see Amino acid § Table of standard amino acid abbreviations and properties. All peptides sequences are assumed to start with NH2- and end with -COOH, unless otherwise stated.
Bariatric surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, have demonstrated effectiveness in promoting weight loss and improving diabetes outcomes among severely obese individuals. A 2021 Evidence Update for Clinicians found that Roux-en-Y gastric bypass patients experienced slightly better weight loss and diabetes control outcomes than sleeve gastrectomy patients, though with a higher risk for rehospitalization and need for additional surgeries. In one study there was an unexplained increase in deaths from accidents and suicide, but this did not outweigh the benefit in terms of disease prevention. When the two main techniques are compared, gastric bypass procedures are found to lead to 30% more weight loss than banding procedures one year after surgery. For obese individuals with non-alcoholic fatty liver disease (NAFLD), bariatric surgery improves or cures the liver. A preoperative diet such as low-calorie diets or very-low-calorie diet, is usually recommended to reduce liver volume by 16-20%, and preoperative weight loss is the only factor associated with postoperative weight loss. Preoperative weight loss can reduce operative time and hospital stay. although there is insufficient evidence whether preoperative weight loss may be beneficial to reduce long-term morbidity or complications. Weight loss and decreases in liver size may be independent from the amount of calorie restriction. Ileojejunal bypass, in which the digestive tract is rerouted to bypass the small intestine, was an experimental surgery designed as a remedy for morbid obesity.
Sources: en.wikipedia.org
They were fought as both irregular warfare and conventional warfare. Some historians claim they began as localized civil wars that spread as secessionist wars for general independence. The new national boundaries followed the colonial provinces and formed the basis of contemporary Hispanic America. Cuba and Puerto Rico remained under Spanish rule until the 1898 Spanish–American War. The Spanish Empire dissolved in the region and new states emerged. The new republics abandoned the Inquisition and noble titles, but slavery was not immediately abolished, and total abolition came only in the 1850s in most countries. Criollos and mestizos replaced Spanish-born officials in most political offices, and Criollos stayed at the top of a social structure that kept traditional features culturally, if not legally. For almost a century, conservatives and liberals fought to reverse or deepen these changes. Spaniards were also subject to forced displacement, during the war and later through expulsion laws meant to consolidate independence. The wars followed the Haitian Revolution (1791–1804) and unfolded alongside Brazil's own path to independence. Spanish America and Brazil shared a trigger: Napoleon's invasion of Iberia, which in 1807 forced the Portuguese royal family to flee to Brazil. More broadly, they drew on the Enlightenment ideas of popular sovereignty behind the Atlantic Revolutions, including the American and French ones. The more direct cause was the crisis within Spain, which ended with new independent states in the post-Napoleonic world.
Spurred by the Pakistan Movement, which sought a homeland for the Muslims of British India, and election victories in 1946 by the All-India Muslim League, Pakistan gained independence in 1947 after the partition of British India, which awarded separate statehood to its Muslim-majority regions and was accompanied by an unparalleled mass migration and loss of life. Initially a dominion of the British Commonwealth, Pakistan adopted a republican constitution in 1956 and became an Islamic republic with two geographically separate provinces, East Pakistan and West Pakistan. East Pakistan seceded as the new country of Bangladesh in 1971 after a nine-month-long civil war. In the following four decades, Pakistan has been ruled by governments that alternated between civilian and military, democratic and authoritarian, relatively secular and Islamist. Pakistan is considered a middle power and is a declared nuclear-weapon state, with the world's seventh-largest standing armed forces. The Pakistani economy is ranked amongst the world's emerging and growth-leading economies, with a large and rapidly growing middle class. Pakistan's political history since independence has been characterised by periods of significant economic and military growth as well as those of political and economic instability. It is an ethnically and linguistically diverse country, with similarly diverse geography and wildlife. The country continues to face poverty, illiteracy, corruption, and terrorism.
== Pharmacology == The main pharmacological effects of flunitrazepam are the enhancement of GABA, an inhibitory neurotransmitter, at various GABA receptors. All benzodiazepines work by enhancing the effect of GABA receptors, which, when active, allow chloride ions to enter the neuron. Negative ions such as chloride inhibit the ability of neurons to fire. It is this stimulation of GABA receptors which is responsible for the depressant effects of benzodiazepines. Flunitrazepam shows high affinity for the α-5 subunit of the GABA-A receptor, which causes some of its unique side effects, such as amnesia. While 80% of flunitrazepam that is taken orally is absorbed, bioavailability in suppository form is closer to 50%. Flunitrazepam has a long half-life of 18–26 hours, which means that flunitrazepam's effects after nighttime administration persist throughout the next day. This is due to the production of active metabolites. These metabolites further increase the duration of drug action compared to benzodiazepines that produce nonactive metabolites. Flunitrazepam is lipophilic and is metabolised by the liver via oxidative pathways. The enzyme CYP3A4 is the main enzyme in its phase 1 metabolism in human liver microsomes.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.